FLT3 and leukemia: In line with our in vitro results, CG-806 had robust anti-leukemia activity in a murine xenograft model of leukemia created using the aggressive FLT3-ITD-mutated Ba/F3 cells (Fig. 5), and in a PDX AML model as well (50).